The ‘streaming wars’ are well underway in November with the launch of Apple’s Apple TV+ and then Disney’s Disney+ last week. The two corporate behemoths have finally entered the fray in an industry that had been dominated by Netflix for as long as it existed.
The competition between these three companies is definitely going to have a profound impact on how millions of people spend their leisure time on a daily basis. Here is a look at some of the important takeaways from the early days of the two new streaming platforms.
Content is King
As everyone knows, content is the most important factor when it comes to the popularity of streaming platforms and in that regard, Disney is way ahead of Apple. It goes without saying that Disney has an enviable archive, having been in the entertainment business for decades. On the other hand, Apple currently offers a few adult and children’s shows, in addition to a documentary on nature.
That being said, it should be noted that Apple’s service costs $4.99 a month, while Disney is offering a plethora of content for only $6.99. It is also important to note that Disney already has content that has an emotional connect with the masses, like Star Wars. On the other hand, Apple has failed to connect with consumers in such a way.
Do Content Providers Stand To Benefit?
According to an article published on Reuters the global video streaming market was valued at $26.27 billion in 2015 and is expected to reach $83.41 billion by 2022 growing at a CAGR of 17.9% from 2015 to 2022. Apple, Disney, Netflix, Amazon, NBC, Hulu & more are all competing within the global video streaming market and they all need the same thing… new & original content. Massive demand may create a huge opportunity for companies like Fearless Films (FERL).
Fearless Films is an independent full-service production company. This is the exact type of company that can benefit from what could become one of the biggest cash grabs in entertainment history and here’s why. You’ve likely heard of the big production houses: Warner Bros, DreamWorks, Red Crown Productions and others who benefited from big deals with streaming companies.
It isn’t just Netflix who’s flexing billions in content budgets, Apple, Amazon, Disney, NBC, Roku – the list goes on. These are huge entertainment distributors who are now fighting for one thing… Where you spend your waking hours streaming entertainment.
And Content Is Still Scarce
The sheer volume of content on Disney Plus will ensure that customers stay on the platform but Apple’s frugal offerings offer no such scope. On the other hand, Disney’s The Mandalorian has already garnered a loyal fan following and the internet is awash with memes about one of the characters. Such viral popularity can always lead to more subscriptions and in that regard; Disney seems to have started its streaming journey very strongly.
Another important thing to point out with regards to these two platforms is that unlike Netflix, they do not drop all episodes at one go. That can often create more hype with regards to popular shows and it remains to be seen what effect it has on the streaming industry at large.
Last but not least, Disney announced that it has already garnered 10 million sign-ups. However, such data should be taken with a pinch of salt since many may have signed up for the one-week free trial. The ‘paying customers’ data is perhaps the more important metric.
Disclaimer: Pursuant to an agreement between Midam Ventures LLC and Fearless Films Inc. (FERL), Midam has been paid $94,980 by Fearless Films Inc. (FERL) for a period from October 1, 2019 to November 17, 2019. We may buy or sell additional shares of Fearless Films Inc. (FERL) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Fearless Films Inc. (FERL). Click Here For Full Disclaimer.
2 Biotech Stocks To Watch Before Next Week
Biotech has been one of the hottest sectors to invest in for quite a few years. Nowadays, investors are almost always on the lookout for the next big thing from among those stocks. However, when it comes to identifying stocks, an investor needs to do his fair share of research and then decide on his next course of action.
Additionally, one could also watch the market closely and keep track of the latest movements in penny stocks in order to identify potential winners. Here is a look at two biotech stocks which could be of interest to investors.
Biotech Stocks To Watch: Marinus Pharmaceuticals
The first biotech stock to bring under consideration is Marinus Pharmaceuticals Inc (NASDAQ:MRNS) which has made significant gains on Wednesday on the back of an important announcement.
On Wednesday, the company announced that it is going to make a simultaneous public offering of its common stock and private placement. The total value of these two offerings is going to be $65 million. The news resulted in a 38% bump in the stock price in yesterday’s trading session.
Earlier this week, the company announced that it has started its Phase 2 trial for its product ganaxolone as well. The medicine in question is supposed to treat tuberous sclerosis complex and it goes without saying that it is a significant milestone for Marinus.
Biotech Stocks To Watch: Diffusion Pharmaceuticals
The other biotech stock that could be worth tracking is that of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN). The company announced positive data with regards to the Phase 3 study its product Trans Sodium Crocetinate (TSC) plus standard of care (SOC). The data showed that there was an improvement in the condition of patients suffering from inoperable glioblastoma multiforme.
It proved to be a major trigger for the Diffusion stock and after the announcement was made on Tuesday, the stock has rallied by as much as 31.40%. It is a stock that could be worth watching over the coming days.
StockPrice.com Subscribers WIN BIG!
We owe you a BIG congratulations. The whole point of StockPrice.com is to bring you important information, first. Sure we send emails out every day on top trending articles and news but we also bring periodic reports on certain companies.
Earlier this year we brought you a full report on a company, PharmaCyte Biotech (PMCB).
Since that report, we’ve watched as PharmaCyte evolved into what it has become today: a biotech powerhouse on the verge of presenting its treatment to the FDA!
Stock Price Subscribers Saw The Full PMCB 90%+ Breakout From August – December; Congratulations! Click Here to Read Our Original Report
This is a great thing for subscribers and we’ve got more featured reports coming! How do you get these reports first?
STEP 1: Make Sure Our Email Address Is In Your Whitelist Address Book So Nothing Gets Lost In Spam
STEP 2:Take Out Your Cell Phone And Text “STOCKPRICE” to 63566. Even If You Miss An Email, We Send Out Updates Directly To Your Cell Phone In Real Time
Again, congratulations to everyone and make sure you stay tuned for our next Stock Price Exclusive Report!
Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. FULL DISCLAIMER HERE
Stock Price Newsletter – December 12, 2019
Are These Biotech Stocks To Buy Or Sell Right Now?
One of the sectors that have proven to be a consistently steady performer in the stock market over the past few years is the biotech sector. Hence, it is not really a surprise that investors are almost always on the lookout for the next big thing among biotech stocks.
The $40 Billion Dollar Content Gold Rush
Apple, Disney, Netflix, Amazon, NBC, Hulu & More are All Competing Within the Global Video Streaming Market and They All Need the Same Thing… New & Original Content! Massive Demand May Create Huge Opportunity for One Company.
3 Penny Stocks To Watch Before The End of 2019: One Up 308%
Penny stocks have often proven to be one of the best classes of stocks to invest in if you like high risk. These cheap stocks allow investors to get into the stock market with a small capital account and buy thousands or even millions of shares of stock at a time. Since these low priced stocks tend to move by pennies at a time, that slight change can equate to large percentage moves.
Join Our Newsletter
Get stock alerts, news & trending stock alerts straight to your inbox!
We keep all user information pricate & promise to never spam.*
Search Stock Price (StockPrice.com)
Biotechnology1 week ago
3 Pharma Stocks To Watch In December 2019
Entertainment2 weeks ago
Is It Time To Buy Or Sell Netflix; Streaming Wars Heat Up
Entertainment2 weeks ago
Disney (DIS) Streaming Business is Getting 1 Million Subscribers a Day
Featured2 weeks ago
Stock Price Black Friday Newsletter – November 29, 2019
Featured2 weeks ago
Stock Price Monday Morning Update – December 2, 2019
Newsletter1 week ago
Stock Price Thursday Morning Update – December 5, 2019
Featured7 days ago
Stock Price Newsletter – December 6, 2019
Featured1 week ago
Stock Price Newsletter – December 3, 2019